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Abstract
Duchenne muscular dystrophy (DMD) is characterized by progressive lethal muscle degeneration and chronic inflammatory
response. The mdx mouse strain has served as the animal model for human DMD. However, while DMD patients undergo
extensive necrosis, the affectedmuscles of adult mdxmice rapidly regenerates and regains structural and functional integrity.
The basis for the mild effects observed in mice compared with the lethal consequences in humans remains unknown. In this
study, we provide evidence that interleukin-6 (IL-6) is causally linked to the pathogenesis ofmuscular dystrophy.We report that
forced expression of IL-6, in the adult mdx mice, recapitulates the severe phenotypic characteristics of DMD in humans.
Increased levels of IL-6 exacerbate the dystrophicmuscle phenotype, sustaining inflammatory response and repeated cycles of
muscle degeneration and regeneration, leading to exhaustion of satellite cells. The mdx/IL6 mouse closely approximates the
human disease and more faithfully recapitulates the disease progression in humans. This study promises to significantly
advance our understanding of the pathogenic mechanisms that lead to DMD.
Introduction
Duchenne muscular dystrophy (DMD) is an X-linked genetic dis-
ease caused by mutations in the dystrophin gene (1). The mdx
mouse strain, lacking a functional dystrophin gene, has served
as the animalmodel for humanDMD (2). However, while the skel-
etal muscles of mdx mice undergo extensive necrosis early in
neonatal life, the affectedmuscle rapidly regenerates and regains
structural and functional integrity (3–7). The basis for themild ef-
fects of the absence of dystrophin observed in mice compared
with the lethal consequences in humans remains unknown.
Among factors possibly explaining the difference between hu-
mans and mdx mice, the extent of chronic inflammatory re-
sponse has been suggested to be linked to the severity of
dystropathology (8,9).
In the present study we have focused our attention on the in-
flammatory cytokine interleukin-6 (IL-6), based on the evidences
that (i) IL-6 increases in DMD patients compared with healthy
subjects (10–12), (ii) high levels of IL-6 promote muscle proteoly-
sis (13–15), (iii) selective modulation of inflammatory response
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ameliorates muscle pathology in mdx mice, reducing IL-6 (16)
and (iv) inhibition of the IL-6 activity (17) and of the intracellular
mediator, namely the JAK/STAT pathway, stimulates muscle re-
generation in both aged and dystrophic mice (18,19). IL-6 is a
pleiotropic cytokine that is produced by different cell types and
has the capacity to induce several different intracellular signaling
pathways (20). IL-6 exerts its biological activities through two re-
ceptors: the membrane-bound and the soluble IL-6 receptors.
The membrane-associated IL-6 receptor on target cells forms a
heterodimer with the cell surface gp130 receptor, and this com-
plex activates intracellular signaling pathways known as clas-
sic-signaling (21). IL-6 trans-signaling requires soluble IL-6R
(sIL-6R) and is possible on all cells of the body since all cells ex-
press the gp130 protein (22).
Based on the activation of either classic or trans-signaling, IL-
6 can promotemarkedly different cellular responses. Of note, IL-6
trans-signaling is pro-inflammatory, whereas classic IL-6 signal-
ing promotes regenerative or anti-inflammatory activities of the
cytokine (21).
Circulating IL-6 levels are normally very low or undetectable
and are markedly increased in several diseases associated with
inflammation, inducing the transition from an acute to a chronic
inflammatory response (23). Circulating IL-6 is also well de-
scribed as predictor of weight loss in human cancer cachexia
(20,24,25) and it contributes to a pathologic state associated
with aging called inflamm-aging (26). IL-6 is also locally and tran-
siently produced in response to exercise and following injury, co-
inciding with the active period of muscle regeneration, and it
plays an important role in satellite cell proliferation, muscle
growth, glucose uptake and fat oxidation (27–29). In contrast, in-
creased muscle proteolysis was found after administration of
high doses or long-term exposure to IL-6 in rodents (13–15). We
demonstrated that treatment of C2C12 myogenic cells with re-
combinant IL-6 resulted in a dramatic inhibition ofmyoblasts dif-
ferentiation (30). Moreover, we recently described the success of
pharmacological inhibition of IL-6 activity, by use of a neutraliz-
ing antibody against the IL-6 receptor, in mdx dystrophic mouse
model at the age in which skeletal muscle is severely compro-
mised and at the stage when the manifestations of the disease
in the mdx mouse model are clearly evident (17). It has been
also reported that treatment of mdx with either Compound A, a
non-steroidal selective glucocorticoid receptor modulator or
with amitriptyline, a tricyclic antidepressant drug, improved
muscle function and decreased serum creatine kinase (CK) levels
and reduced pro-inflammatory cytokines expression, including
IL-6 (16,31).
The conflicting activity of IL-6 and the apparent discrepancy
among different studies can be justified considering that the
positive effects of IL-6 are normally associated with its transient
production and short-term action (20,32,33) and that IL-6 might
exert opposite roles in different cell types. In addition, a chronic
elevation of circulating IL-6 is often associated with an under-
lying disease, and specific aspects of different disease states
could serve to alter the systemic and tissue level response to ele-
vated IL-6.
To add new insights into the pathogenesis of muscular dys-
trophy and to determine the basis for the milder phenotype ob-
served in adult mdx mice, compared with young mice and to
human patients, we crossed the mdx mice with IL-6 overexpres-
sing mice, which accumulate high levels of circulating IL-6 since
early phases of life (34). In the present study, we found that IL-6
was indeed expressed at higher levels in the diaphragm of
4-week-old mdxmice compared with 24-week-old mdx animals,
possibly suggesting that a down-regulation of this cytokine
might contribute to an amelioration of dystrophic phenotype ob-
served in the adult (3). Increased levels of IL-6 induced, in mdx/
IL6 mice, the severe features and progressive nature of human
DMD, in a stage normally spared by the absence of dystrophin,
suggesting that IL-6 is causally linked to the pathogenesis of
muscular dystrophy.
Results
Down-regulation of inflammatory cytokines correlates
with amelioration of the dystrophic phenotype in mdx
mice
A pathogenic feature associated with the severity of dystro-
pathology is the necrosis of muscle fibers, accompanied by in-
flammatory response (35,36). Necrosis was significantly reduced
in the diaphragm muscle of 24-week-old mdx mice compared
with 4-week-old mdx mice (Fig. 1A). Of note, we also observed a
significant reduction in utrophin (Utrn) expression in the dia-
phragm of 24-week-old mdx mice compared with 4-week-old
mdx mice (Fig. 1B), further supporting the hypothesis of activa-
tion of compensatory mechanism in adult dystrophic muscle
(37,38), leading to sarcolemma integrity. The reduced damage
in the diaphragm of adult mdxmice would also suggest a modu-
lation of the inflammatory response, which is a prominent fea-
ture of the pathogenesis of muscular dystrophy (9,39). We
analysed the expression levels of IL-6, TNFα and IL-1β, important
mediators of the inflammatory response (40,41), in the dia-
phragm ofmdxmice at 4 and 24weeks of age. Real time PCR ana-
lysis revealed that the expression of IL-6 (Fig. 1C), IL-1β (Fig. 1D)
and TNFα (Fig. 1E) was significantly up-regulated in diaphragm
of 4-week-old mdx mice, compared with wild-type littermates.
Among these cytokines, IL-6 was the only one significantly
down-regulated in the diaphragm muscle of 24-week-old mdx
mice, compared with 4-week-old mdx mice (Fig. 1C). The down-
regulation of IL-6 in the diaphragmof 24-week-oldmdxmicewas
also associated with the reduced expression of SOCS3 (Fig. 1F), a
negative regulator of IL-6 signaling (42,43), and of gp130 (Fig. 1G)
and IL6Rα (Fig. 1H), the two IL-6 receptors that mediate the IL-6
signaling (22).
To further support the evidence of reduced inflammatory re-
sponse in the diaphragmmuscle of 24-week-oldmdxmice, com-
pared with 4-week-old mice, we evaluated relevant markers of
the anti-inflammatory response, such as IL-1ra and SLPI. Real
time PCR analysis revealed a significant up-regulation of IL-1ra
(Fig. 1I) and SLPI (Fig. 1J) expression in the diaphragm of adult
mdx mice.
These data are consistent with the hypothesis that the down-
modulation of IL-6 signaling might be sufficient to mitigate the
inflammatory response in dystrophic muscles and, possibly, to
attenuate the muscle phenotype observed in adult mdx mice.
IL-6 overexpression increases the numberof regenerating
centro-nucleated fibers in mdx mice
In order to evaluate the potential role of IL-6 overexpression on
adult dystrophic phenotype, we generated the mdx/IL6 mouse
model, by crossing mdx mice with IL-6 transgenic mice that ex-
press high levels of circulating IL-6 since early after birth (34).
We evaluated, by ELISA, both endogenous and transgenic
plasma circulating levels of IL-6 in wild-type, mdx and mdx/IL6
mice of 24weeks of age (Fig. 2A and B). As expected, the endogen-
ous levels of circulating IL-6 were very low in wild-type mice and
increased in both mdx and mdx/IL6 mice (Fig. 2A). Nevertheless,
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we did not observed any significant change in endogenous circu-
lating levels of IL-6 between mdx and mdx/IL6 mice (Fig. 2A). In
contrast, ELISA revealed a dramatic increase of circulating levels
of transgenic IL-6 inmdx/IL6mice, comparedwith bothwild-type
andmdxmice (Fig. 2B).We also evaluated the expression levels of
IL-6 in the diaphragm of wild-type, mdx and mdx/IL6 mice. The
levels of muscle expression of IL-6 were increased in both mdx
and mdx/IL6 mice of 24 weeks of age, compared with wild-type
littermates (Fig. 2C); however there was no statistical difference
in the expression levels of muscle IL-6 between mdx and mdx/
IL6 mice (Fig. 2C). Interestingly, IL-6 receptor alpha, which med-
iates the IL-6 trans-signaling, was significantly up-regulated in
the muscle of 24-week-old mdx/IL6 mice, compared with both
wild-type and mdx littermates (Fig. 2D).
To determinewhether increased levels and activity of IL-6 ex-
acerbate the dystrophic muscle phenotype, a direct comparison
ofmorphological parameterswas performed for diaphragmmus-
cle of mdx and mdx/IL6 mice at 24 weeks of age. The analysis re-
vealed a significant increase in the number of small centrally
nucleated fibers (CNFs) (Fig. 2E), which represents amorphologic-
al feature of newly regenerating fibers and an indication of on-
going regeneration (39), in the muscle of 24-week-old mdx/IL6
mice. Notably, the average cross-sectional area (CSA) of centro-
nucleated fibers with 1 and 2 nuclei were also significantly
Figure 1. The down-modulation of IL-6 correlates with the stabilization of dystrophic phenotype. (A) Confocal microscopy (left panels): representative images of Evans
Blue Dye (EBD) staining of whole diaphragm muscles from mdx mice at 4 weeks (4W, n = 5) and 24 weeks (24W, n = 4) of age. The images show necrotic fibers in red and
optical phase in white. Scale bar, 200 μm. Graph showing quantification of EBD uptake (right panel) performed on 160–210 optical sections with a step size of 10 μm, from
whole diaphragms of indicated genotypes. EBD is significantly more diffuse (72%) in the diaphragm of 4-week-old mdx than in the diaphragm of 24-week-old mdxmice.
Values representmean ± SEM. P value byMann–Whitney test. (B–J) Real time PCR analysis performed ondiaphragmmuscles fromwild-type (WT) andmdxmice at 4 and 24
weeks of age, for the expression of Utrn (B), IL-6 (C), IL-1β (D), TNFα (E), SOCS3 (F), gp130 (G), IL6Rα (H), IL-1ra (I) and SLPI (J). Values represent mean ± SEM; n = 4–9 mice per
group. ***P < 0.0005, **P < 0.005, *P < 0.05, compared with WT mice; ##P < 0.005 #P < 0.05 between 4-week-old and 24-week-old mdx mice (by ANOVA).
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smaller in the muscle of 24-week-old mdx/IL6 mice, compared
withmdx littermates (Fig. 2F). Interestingly, CSA of both regener-
ating and not-regenerating myofibers was smaller in diaphragm
muscle of the 24-week-oldmdx/IL6mice compared withmdx lit-
termates (data not shown), suggesting that IL-6 negatively influ-
ences the myofiber size of dystrophic muscle. Since the reduced
myofiber CSA in mdx/IL6 diaphragm could depend on the IL-6
smaller mouse (34) and in order to verify whether IL-6 overex-
pression affects the growth rate of mdx mice, we analysed and
compared the growth curves of wild-type, IL-6 transgenic, mdx
and mdx/IL6 mice (Fig. 2G). We observed that elevated levels of
circulating IL-6 induced a similar growth defect in both IL-6 and
mdx/IL6 mice (Fig. 2G), compared with wild-type and mdx mice.
This indicates thatmuscular dystrophy does not further increase
the effects of IL-6 on growth defect. To confirm these datawe cal-
culated the muscle weight/body weight ratio in wild-type, IL-6
transgenic, mdx and mdx/IL6 mice at 24 weeks of age (Table 1).
As shown in Table 1, the significant reduction of diaphragm
mass in mdx/IL6 mice was related to the decrease of the body
weight, leading to a similar muscle weight /body weight ratio be-
tween mdx/IL6 and mdx mice.
These data reveal that: (i) increased circulating levels of IL-6
cause growth defect in IL-6 transgenic and mdx/IL6 dystrophic
mice, (ii) IL-6 sustains a continuous cycle of muscle regeneration
when overexpressed in the context of muscular dystrophy.
Increased levels of IL-6 enhance the susceptibility
of dystrophic muscle to damage
We then performed experiments to substantiate the hypothesis
that increased levels of IL-6 exacerbate the dystrophic phenotype
and negatively influence the lifespan of mdx mice.
Of note and conversely to the DMD patients, the lifespan of
mdx mice is comparable to healthy wild-type mice (44). We ob-
served that high levels of circulating IL-6, in the context of the
dystrophic genotype, significantly reduced the survival of mdx/
Figure 2. Increased levels of IL-6 enhance the number of regenerating centro-nucleated fibers in mdx mice. (A and B) Circulating levels of endogenous IL-6 (A) and of
transgenic IL-6 (B) was evaluated by ELISA on serum from 24-week-old wild-type (WT), mdx and mdx/IL6 mice. Values represent mean ± SEM; n = 5–10 mice per group.
**P < 0.005 between 24-week-old mdx mice and WT littermates; *P < 0.05 between 24-week-old mdx/IL6 and WT mice (by t-test). ND, no detected. (C and D) Real time
PCR analysis for the expression of IL-6 (C) and IL6Rα (D) in diaphragm of 24-week-old WT, mdx and mdx/IL6 mice. Values represent mean ± SEM; n = 4–8 mice per
group. *P < 0.05 compared with WT littermates (by t-test for panel C); ***P < 0.0005 compared with WT mice, ###P < 0.0005 between mdx/IL6 and mdx mice (by ANOVA
for panel D). (E and F). Quantification of total number of CNFs per μm2 (E) and of the average cross sectional area (CSA) of CNFs with 1 and 2 nuclei (F) in muscles of
24-week-old mdx and mdx/IL6 mice. Values represent mean ± SEM; n = 5 mice per group. ###P < 0.0005, ##P < 0.01 using Mann–Whitney test. (G) Growth curves of wild-
type (WT, n = 17), IL-6 transgenic (IL-6, n = 5), mdx (n = 8) and mdx/IL6 (n = 16) mice. Values represent mean ± SEM. ###P < 0.001 between IL-6 transgenic and WT mice;
***P < 0.001 between mdx/IL6 and mdx mice using two-way ANOVA.
Table 1. Body weight and diaphragm mass of wild-type, IL-6 transgenic, mdx and mdx/IL6 mice at 24 weeks of age
Wild type P Value IL-6 P Value mdx P Value mdx/IL6 P Value
versus
IL-6
versus
mdx/IL6
versus
WT
versus
mdx
Body weight (g) 35.81 ± 7.71 0.0005 23.22 ± 4.02 ns 37.93 ± 6.44 ns 28.59 ± 3.70 0.005
Diaphragm weight (g) 0.09 ± 0.02 0.005 0.07 ± 0.01 0.0005 0.16 ± 0.04 0.0005 0.13 ± 0.03 0.05
Muscle weight/Body
weight ratio
0.0026 ± 0.0005 ns 0.0028 ± 0.0006 0.0005 0.0041 ± 0.0007 0.0005 0.0044 ± 0.0008 ns
Note: Data represent the means ± SD of at least nine animals per group. IL-6 = IL-6 transgenic mouse. P values by one-way ANOVA. ns = not significant.
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IL6mice by 100 days to amaximal life span of 400 days (P < 0.001),
compared with mdx mice (Fig. 3A).
One of the pathogenic events associated with DMD is the con-
tinuous cycle of degeneration and regeneration (4). The presence
of small regeneratingfibers in themuscle of 24-week-oldmdx/IL6
mice would reflect an active myofibre necrosis. We thus evalu-
ated, by Evan’s blue dye staining (EBD), the degree of muscle de-
generation (45) in the diaphragmmuscle of 24-week-oldmdx and
mdx/IL6 mice (Fig. 3B). The areas and the number of necrotic fi-
bers within the injured area (Fig. 3B bottom panel) were signifi-
cantly larger in the diaphragm of mdx/IL6 mice than in the
mdx littermates. Another feature of muscle degeneration is the
release of muscle enzymes, generally assayed as CK, into the cir-
culation (46). We found a significant increase of serum CK levels
in 24-week-old mdx/IL6 mice compared with mdx littermates
(Fig. 3C).
Muscle damage leading to regeneration, is normally asso-
ciated to activation of the inflammatory response (39). Histologic-
al and histochemical analysis revealed an accumulation of
infiltrating mononuclear cells (Fig. 3D top panels) and an in-
creased concentration of myeloperoxidase (MPO)-positive cells
(Fig. 3D bottom panels) within the muscle of 24-week-old mdx/
IL6 mice, compared with mdx muscle. The damage of muscle fi-
bers might compromise muscle force-producing capacity. We
evaluated the EDL muscle function, namely the capacity to pro-
duce force, of 24-week-old wild-type, mdx and mdx/IL6 mice.
The mdx/IL6 muscle showed significantly greater drop in force
between the first and fifth contractions compared with mdx
and wild-type littermates (Fig. 3E). To define, in a more physio-
pathological context, the alteration in the functional perform-
ance of mdx/IL6 dystrophic muscle, we forced mice to run on a
treadmill, which is also used to accelerate muscle weakness to
more closely mirror the muscle pathology seen in patients with
DMD (47–51).
We applied a protocol of 30 min running on a horizontal mo-
torized treadmill, equipped with a grid, at a speed of 12 m/min,
twice a week for 5 weeks (49), starting at 24 weeks of age. We re-
vealed a significant reduction in the functional performance of
mdx/IL6 mice, compared with mdx and wild-type littermates
(Fig. 3F). In particular, themdx/IL6mice covered aminor distance
compared with mdx mice littermates (Fig. 3F). We noted that the
mdx/IL6 mice received more stimuli to run (either electric foot
shock or tongue depressor stimulation) and remained on the
grid for an extended period of time compared with mdx litter-
mates. The mdx/IL6 mice were exhausted after the exercise ses-
sion and remained prostrated in the cages for an extended period
of time compared with mdx littermates.
Molecular mediators of IL-6 pathologic activity
in dystrophic muscle
One of the central players implicated in inflammation and mus-
clewasting and a pathogenic factor in DMD isNFkB (52–55).West-
ern blot analysis revealed a significant increase of NFkB
phosphorylated active form (Fig. 4A) in the diaphragm from 24-
week-oldmdx/IL6mice comparedwithmdx littermates. Notably,
the expression levels of NFkB were not significantly different in
the muscles of 24-week-old wild-type and mdx mice (Fig. 4A).
TNFα expression (Fig. 4B), a potent NFkB inducer and a cytokine
that mediates skeletal muscle protein degradation (56,57) was
up-regulated in the muscle of both 24-week-old mdx and mdx/
IL6 mice compared with wild-type littermates. Of note, TNFα ex-
pression resulted significantly up-regulated in the diaphragm of
mdx/IL-6 compared with mdx littermates (Fig. 4B). These data
further support the evidence that the mild muscle phenotype
of adultmdxmice is due to the reduction in the inflammatory re-
sponse, whereas the inflammatory infiltrate that characterize the
muscle ofmdx/IL6micemight play amajor role in promoting the
pathology of dystrophin-deficient muscle. Indeed, the enhanced
inflammatory response and the exacerbated dystrophic pheno-
type of mdx/IL6 mice were also associated with a significant
down-regulation of the anti-inflammatory modulators IL-1 re-
ceptor antagonist (IL-1ra) (Fig. 4C) and of SLPI (Fig. 4D) (58,59).
Increased levels of IL-6 contribute to the exhaustion
of muscle stem cells (MuSCs)
One of the pathological features of the severe dystrophic pheno-
type is a continuous cycle of degeneration and regeneration that
is exacerbated inmdxmice by increased levels of IL-6. To support
morphological analysis (Fig. 2E and F; Fig. 3) and verify the behav-
ior of satellite cells, we evaluated the expression of Pax-7, amark-
er of quiescent and activated satellite cells (60,61) and Desmin, a
specific marker of satellite cells activation and proliferation
(62,63). The transcripts (Fig. 5A and C) and proteins (Fig. 5B and D)
of both Pax-7 and Desmin resulted significantly up-regulated in
themuscle of 24-week-oldmdx/IL6mice compared withmdx lit-
termates. These data suggest that increased levels of circulating
IL-6 interfere with muscle homeostasis and stimulate a continu-
ous satellite cells proliferation (64), eventually leading to exhaus-
tion of the pool of MuSCs.
To validate this hypothesis, we analysed, in both 36-week-old
mdx andmdx/IL6 mice, the percentage of MuSCs. Accordingly to
previouswork, the percentage ofMuSCswere determined byflow
cytometry as CD34pos/α7-integrinpos/Sca1neg/CD45neg/CD31neg
cells (65). CD34pos/α7-integrinpos cell populationwas significantly
reduced in the muscle of mdx/IL6 mice compared with mdx lit-
termate (Fig. 5E). Because the combination of CD34 and α7-integ-
rin expression is limited to quiescent self-renewal MuSCs with
myogenic activity (65,66), the reduction in this population sug-
gests that accumulation of circulating IL-6 levels causes an ex-
haustion of MuSCs. Of note, cytofluorimetric profile revealed
also an increase in the percentage of linneg/Sca1pos/CD34pos/α7-
integrinneg cells. These cells have been recently described as
fibro/adipogenic progenitors (FAPs), which modulate muscle re-
generation in healthy muscle and contribute to fibrosis under
pathologic conditions (66–71). Our data suggest that increased le-
vels of IL-6 create an hostile microenvironment that affects
MuSCs maintenance and exacerbates the dystrophic phenotype.
Discussion
In this study, we contributed to define the pathogenic role of IL-6
in the exacerbation of the dystrophic phenotype in mdx dys-
trophic mouse model.
A longstanding open question in the field of muscular dys-
trophy has beenwhyDMDpatients display a severemusclewast-
ing, whereas themdxmouse strain, with the samemutation, has
a nearly normal lifespan and does not develop severe phenotype
(3). The basis for themild effects observed inmice comparedwith
the lethal consequences in humans remains unknown. In our
study, we addressed whether a critical component of the im-
mune system, namely the pro-inflammatory cytokines IL-6,
plays a pivotal role in the pathogenesis of DMD.
The rationale to study the role of IL-6 on the pathogenesis of
muscular dystrophy was based on the evidence that: (i) the in-
flammatory cytokine IL-6 concentrations are significantly higher
in the serum of DMD patients compared with healthy age-
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Figure 3. IL-6 overexpression exacerbates the dystrophic phenotype. (A) Kaplan–Meier survival curves of indicated genotypes. n = 39–98mice per group. P value compared
withmdxmice using long-rank test. (B) Top panels: Representative images of Evans blue dye (EBD) staining of transverse section of diaphragm from 24-week-oldmdx and
mdx/IL6 mice. Bottom panels: quantification of necrotic areas and of Evans-blue-dye positive cells within necrotic area (necrotic fiber) in diaphragm of 24-week-old mdx
andmdx/IL6mice. Scale bar, 100 μm.Values representmean ± SEM; n = 5mice per group. P values, comparedwithmdxmice usingMann–Whitney test. (C) SerumCK levels
in 24-week-old mice of indicated genotypes. Values represent mean ± SEM; n = 6–7mice per group. ***P < 0.0005, *P < 0.05 compared withWT littermates; #P < 0.05 between
mdx/IL6 andmdxmice using one-way ANOVA. (D) Representative image ofMPO staining (top panels) of transverse section of diaphragm from24-week-oldmdx andmdx/
IL6 mice. Bottom panel shows the evaluation of the number of phagocytic cells (MPO-positive-cells) in diaphragm of 24-week-old mdx and mdx/IL6 mice. Scale bar,
100 μm. MPO+ cells (black arrows) are much more in number in the diaphragm of mdx/IL6 than in the diaphragm of mdx mice. Values represent mean ± SEM; n = 5 per
group. P value compared with mdx mice using Mann–Whitney test. (E) The graph shows the progressive drop in force during five subsequently electrical stimulations
(stimuli) in EDL muscle from WT, mdx and mdx/IL6 mice of 24 weeks of age. Values represent mean ± SEM; n = 5–6 mice per group. **P < 0.01, ***P < 0.001 compared with
WT littermates; §§P < 0.01, §§§P < 0.001 comparedwithmdxmice using two-way ANOVA. (F) Quantification of treadmill test onwild-type (WT), mdx andmdx/IL6mice of 24
weeks of age. The graph shows the covered distance, by indicated genotypes, in a given time at 10, 20 and 30 min of the running test. Values represent mean ± SEM; n = 3
mice per group. P value using two-way ANOVA.
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matched (12,17); (ii) IL-6 concentrations follow the disease time-
course in human DMD (12); (iii) among pro-inflammatory cyto-
kines, IL-6 was the only one significantly down-regulated in the
muscle of 24-week-oldmdxmice (Fig. 1), comparedwith younger
mice, which represents a stage normally spared from the absence
of dystrophin (7,72,73).
We postulated that the mild muscle wasting phenotype ob-
served in adult (24-week-old) mdx mice, compared with young
(4-week-old) mdxmice is due to the reduction in IL-6 expression.
To substantiate this hypothesis, mdx mice and IL-6 transgenic
mice (34), which accumulate IL-6 in the blood since birth, were
used to generate the mdx/IL6 transgenic animals. The mdx/IL6
mice displayed a dramatic and selective increase of circulating
levels of transgenic IL-6, compared with both wild-type and
mdx mice.
Our data in mdx/IL6 mice, show that increased circulating
levels of IL-6 cause reduction in survival of dystrophic mouse
model, increase muscle necrosis and inflammation, sustain re-
peated cycles of muscle degeneration and regeneration and con-
tribute to exhaustion of satellite cells, leading to exacerbation of
the dystrophic muscle phenotype. Therefore, we provided evi-
dences demonstrating that sustained increase in the levels of
IL-6 alone is sufficient to exacerbate the dystrophic phenotype
at a stage, 24 weeks of age, when only a mild muscle phenotype
is apparent inmdxmice (3). This indeed complements the obser-
vation of a selective down-regulation of IL-6 in the diaphragm of
24-week-old mdx mice compared with 4-week-old mdx mice.
We then characterized the potential molecular pathways that
mediate the catabolic effects of increased levels of IL-6. IL-6 exhi-
bits pro-inflammatory activity through activation of the tran-
scription factor nuclear factor κB (NFkB), which represents also
a key mediator of muscle wasting in different pathologic condi-
tions, including DMD (74,75). We observed a significant up-regu-
lation ofNFkBandTNFα expression, potent inducer ofNFkB anda
cytokine that mediates skeletal muscle protein degradation
(56,57), in the diaphragm of 24-week-old mdx/IL6 mice.
Another pathogenic event associated with DMD is the ex-
haustion of satellite cells that replace damaged fibers, due to a
continuous process of degeneration and regeneration. The per-
sistent activation of satellite cells observed in mdx/IL6 muscles
supports the evidence that IL-6 is an importantmediator of satel-
lite cell proliferation (64).We reasoned that the repeated cycles of
degeneration/regeneration, induced by IL-6 overexpression,
might contribute to the exhaustion of MuSCs) and, therefore, to
the exacerbation of the dystrophic phenotype. Indeed, cytofluori-
metric profile revealed a significant reduction of MuSCs in
mdx/IL6 muscles compared with mdx one, associated with an
increase in Sca1pos fibro/adipocytic infiltration. This suggests
that increased levels of IL-6 generate an unfavorable microenvir-
onment, which stimulates fibroadipogenic progenitors (FAPs)
proliferation/activity. In the context of healthymuscle, FAPs pro-
vide an environment that favors myogenic differentiation (66).
However, in chronic injury, such as muscular dystrophy, FAPs
contribute to disease progression by influencing the activity of
satellite cells (66–68). Interestingly, FAPs represent an inducible
source of IL-6 (66). Although we specifically analysed the effect
of increased levels of IL-6 on FAPs population, we cannot exclude
an alteration in the activity of other precursor cells, which pre-
sent a similar molecular signature of FAPs, namely mesoangio-
blasts, PW1+ interstitial cells (PICs) and Side population (SP)
cells (76–78), whose alteration can in turn hinder FAPs function
and muscle homeostasis. Of note, our work also supports recent
studies, demonstrating that elevated Stat3, a down-stream ef-
fector of the pro-inflammatory cytokine IL-6, inhibits satellite
cell function and impair regeneration during aging and disease
progression (18,19).
One open question is whether IL-6 directly targets skeletal
muscle or alternatively works through indirect mechanisms.
Our data suggest that both mechanisms can be envisaged in
the context of muscular dystrophy. Interestingly, we did not
observed any significant change in endogenous muscle levels
of IL-6 between mdx and mdx/IL6 mice. Several evidences
Figure 4.Molecularmediators of dystrophicmuscle by IL-6 overexpression. (A)Western blot (right panel shows a representative image) analysis for NFkB active (NFkB p65)
and total (NFkBTOT) proteins, performed ondiaphragmof 24-week-oldWT,mdx andmdx/IL6mice. Values representmean ± SEM; n = 5–10 per group. **P < 0.005 compared
withWTmice; #P < 0.05 betweenmdx/IL6 andmdx littermates (by one-way ANOVA). (B–D) Real time PCR analysis for the expression of TNFα (B), IL-1ra (C) and SLPI (D) on
diaphragmof indicated genotypes at 24weeks of age. Values representmean ± SEM; n = 4–7 per group. ***P < 0.0005; **P < 0.005; *P < 0.05 comparedwithWTmice; ##P < 0.005;
#P < 0.05 between mdx/IL6 and mdx littermates (by one-way ANOVA). In A the lanes were run on the same gel but were non contiguous.
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indicate that contractingmuscle fibers themselves are a source of
IL-6 mRNA and protein (28,33). Under physiologic conditions
such as exercise, IL-6 is rapidly and markedly increased (79). Of
note, the fact that the classical pro-inflammatory cytokines,
TNFα and IL-1β, in general do not increasewith exercise indicates
that the cytokine cascade induced by exercise markedly differs
from the cytokine cascade induced by infections or diseases
(80). Themuscle-induced IL-6 can act in an autocrine or paracrine
manner, stimulating anabolic pathways associated with muscle
growth, myogenesis and with regulation of energy metabolism
Figure 5. Increased levels of IL-6 induce exhaustion ofMuSCs and accumulation of FAPs. (A andC) Real time PCR analysis for the expression of Pax-7 (A) andDesmin (C) on
diaphragm of 24-week-old wild-type (WT), mdx and mdx/IL6 mice. Values represent mean ± SEM; n = 5–7 per group. P values using one-way ANOVA. (B and D)
Densitometric analysis (right panels) and representative images (left panels) of western blot analysis for the expression of Pax-7 (B) and Desmin (D) on diaphragm of
24-week-old wild-type (WT), mdx and mdx/IL6 mice. Values represent mean ± SEM; n = 5–9 per group. ***P < 0.0005; **P < 0.005; *P < 0.05 compared with WT mice;
#P < 0.05 between mdx/IL6 and mdx littermates (by ANOVA). (E) Cytofluorimetric analysis of freshly isolated cells from muscles of 36-week-old wild-type (WT), mdx
and mdx/IL6 mice. Living cells were gated for 7-AAD low. Cells negative for CD45 and CD31, markers of macrophages, hematopoietic and endothelial cells, were gated
and analysed for the expression of Sca1 and α7-integrin. Within α7-integrin+/Sca1− population (red gate) the muscle satellite cells (MuSCs) were identified as lin−/α7-
integrin+/Sca1−/CD34+ cells. α7-integrin−/Sca-1+ cells (blue gate) identified fibro/adipogenic progenitors (FAPs) and over 92% of these cells expressed CD34. n = 4
independent experiments. P < 0.05 compared with mdx littermates using student’s two-tailed t-test. In B, D the lanes were run on the same gel but were non contiguous.
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(33). In contrast, under pathologic conditions, such as muscular
dystrophy, cancer associated cachexia and other diseases, in
which the plasma levels of IL-6 significantly increase, the anabol-
ic muscle activity of IL-6 might be impinged and prevails the per-
sistent and systemic activity of IL-6, which promote muscle
wasting with the possible participation of other mediators (33).
Interestingly, we observed a significant up-regulation of the
IL-6 receptor alpha, which mediates the IL-6 trans-signaling, in
the muscle of 24-week-old mdx/IL6 mice compared with both
wild-type and mdx littermates (Fig. 2). This suggests that the in-
creased plasma levels of IL-6, in the mdx/IL6 mice, can directly
target skeletal muscle, altering muscle homeostasis and/or
indirectly, stimulating the activity of factors that contribute to
myonecrosis, increased inflammation and altered regenerative
mechanisms.
Of note, overexpression of IL-6 in a non-dystrophic animal
model, although causes growth impairment, does not induce
any active inflammation, necrosis, regeneration or fibrosis in
muscle (34 and data not shown). The transgenic mice have nor-
mal food intake and a normal life span, with no peculiar suscep-
tibility to infections (34). Thus, in the context of muscular
dystrophy, increased circulating levels of IL-6 might synergize
with other factors, creating an hostilemicroenvironment and ex-
acerbating the dystrophic phenotype.
In summary, we describe the generation of a newDMDmouse
model that closely approximates the human disease and more
faithfully recapitulates the disease progression in humans. Our
work is consistent with a model (Fig. 6) in which increased circu-
lating levels of IL-6 exacerbate the dystrophic phenotype, pro-
moting muscle degeneration, inflammation, exhaustion of
MuSCs and accumulation of FAPs. This study also indicate a po-
tential therapeutic approach to counter the secondary symptoms
caused by the primary loss of dystrophin, namely necrosis, in-
flammation and alteration in the regenerative mechanisms. In-
deed, more recently, we demonstrated that inhibition of IL-6
activity, using an IL-6 receptor neutralizing antibody, conferred
robustness to dystrophic muscle, significantly reduced necrosis,
impeded the activation of a chronic inflammatory response, acti-
vated the circuitry of muscle differentiation and maturation,
guaranteeing a functional homeostatic maintenance of dys-
trophic muscle (17). These findings were paralleled by inhibition
of NFkB expression and withmodulation of the inflammatory re-
sponse, including down-regulation of TNFα and up-regulation of
the anti-inflammatory mediators IL-1ra and SLPI, and with a
down-regulation of Desmin, a marker of proliferating satellite
cells (63,81). Interestingly, all of these factors were modulated
in mdx/IL6 muscle, suggesting that IL-6 leads to changes in the
dystrophic muscle environment, conditioning inflammatory re-
sponses and muscle repair.
Thus, our study promises to significantly advance our under-
standing of the pathogenic mechanisms that lead to muscular
dystrophy and to provide the rationale for pharmacological treat-
ment of DMD patients.
Material and Methods
Mice
Mdx mice (Jackson Laboratories) and IL-6 transgenic mice (34),
which overexpress human IL-6 since birth, were used to generate
themdx/IL6 transgenic animals. IL-6 transgenicmicewere previ-
ously generated using the NSE/hIL-6 construct, which carries the
rat neurospecific enolase (NSE) promoter driving the expression
of human IL-6 complementary DNA (34). Overexpression of IL-6
does not induce any neural alteration nor active inflammation,
necrosis or fibrosis in muscle (34). The transgenic mice have nor-
mal food intake and hematic glucose as well as a normal life
span, with no peculiar susceptibility to infections and no defects
in the numbers of spleen T cells and B cells (34).
All animal experiments were approved by the ethics commit-
tee of Sapienza University of Rome-Unit of Histology andMedical
Embryology and were performed in accordance with the current
version of the Italian Law on the Protection of Animals.
Force measurements
Twenty-four-week-old mice were sacrificed and force measure-
ments of extensor digitorum longus (EDL) muscle were per-
formed ex vivo as reported (82,83). To evaluate the decline of
force, five tetanic stimulation were imposed to the muscle with
a recovery period of 2 m between each of them. Drop of force
was evaluated as the value of force developed during the last
stimulation (F5) divided for the initial value of force (F1), ex-
pressed in percentage: F5/F1%.
Treadmill tests
The treadmill tests were performed using the LE8700 Treadmill
Control (Panlab sl). Twenty-four-week-old wild-type, mdx and
Figure 6. A schematic model depicting the effects of increased plasma levels of IL-6 on dystrophic muscle. Increased levels of IL-6 promote necrosis and inflammation,
stimulating a continuous cycle of degeneration and regeneration, leading to exhaustion of MuSC and accumulation of fibro/adipocytic infiltration. All of these contribute
to exacerbate the dystrophic phenotype.
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mdx/IL6 mice were acclimated to treadmill running at 5 m/min
for 5 min for two times. The mice ran for 30 min on a horizontal
treadmill at a speed of 12 m/min, twice a week for 5 weeks. Dis-
tance (meter) was measured at 10, 20 and 30 min of running.
We used a motorized treadmill equipped with a gentle inten-
sity shock grid. Animals who quit running were pushed by the
moving treadmill belt onto a grid that delivers an electric foot
shock; to escape the negative stimulus, the mice return to run-
ning on the belt. To avoid potential stress caused by the shock ap-
paratus we also used an alternative gentle encouragement, by a
human operator, that is a tongue depressor, coupled with sensi-
tivity to the voluntarywillingness to run on the part of themouse
(84). Of note, the results obtained with the two alternative meth-
ods of encouragement were comparable in all animals analysed.
Evans blue staining and confocal microscopy
Intraperitoneal injection of Evans blue dye (EBD) (100 μl of 1% EBD
per 10 g of body mass) was performed on a minimum of four an-
imals/strain (24-week-old wild-type, mdx and mdx/IL6 mice), as
described (85). Fluorescent fibers were viewed under an inverted
microscope (Axioskop 2 plus; Carl Zeiss Microimaging, Inc.), and
images were processed using Axiovision 3.1. and analysed using
Scion Image 4.0.3.2. software. Confocal microscopy (Leica Laser
Scanning TCS SP2) was used to analyse the total intensity of
EBD fluorescence, which represent the full amount of fluores-
cence held within the entire z-axis of the series, in 4-week-
old mdx and 24-week-old mdx whole diaphragm muscles.
Approximately 160 optical sections, from at least three separate
experiments, were analysed. The images were processed and
analysed using LAFAF Lite software (Leica). Acquisition and ana-
lysis was performed in a blinded fashion, using coded slides.
Histological analysis
Segments of diaphragm from a minimum of five animals/strain
(24-week-old wild-type, mdx and mdx/IL6 mice) were embedded
in tissue freezing medium and snap frozen in nitrogen-cooled
isopentane. For general morphology, cryostat sections were
stained with hematoxylin and eosin (H&E) according to standard
protocols. Bright-field images were visualized using an Axioskop
2 plus (Carl Zeiss Microimaging, Inc.) and analysed using Scion
Image 4.0.3.2. software to quantify: (i) the number of fibers with
central nuclei per field and (ii) the mean of cross-sectional area
(CSA) of centrally nucleated myofibers. For each tissue section
analysed, a minimum of 300 muscle fibers were counted. Myelo-
peroxidase staining (SIGMA) was used to quantify the number of
phagocytic cells per field. Histological evaluations were per-
formed in a blinded manner, using coded slides.
Protein extraction, Western blot analysis and ELISA
Diaphragm muscles from at least five animals/strain (wild-type,
mdx andmdx/IL6mice) were homogenized inmodified lysis buf-
fer [Tris–HCl, ph 7.5/20 m, EDTA/2 m, EGTA/2 m, sucrose/
250 m, DTT/5 m, Triton-X/0.1%, PMSF/1 m, NaF/10 m,
SOV4/0.2 m, cocktail protease inhibitors/1X (Sigma)]. Filters
were blotted with antibodies against: Pax-7, Desmin, NFkBp65
(ser536), NFkB (Cell Signaling); GAPDH (Santa Cruz). Signals
were captured by ChemiDoc-It® Imaging System (UVP, LLC) and
densitometric analysis was performed with VisionWorks®LS
Image Acquisition and Analysis Software. Elisa assay was per-
formed to detect murine and transgenic IL-6 using Quantikine®
Colorimetric Sandwich ELISAs (R&D Systems), according toman-
ufacturer’s protocol.
RNA extraction and quantitative RT-PCR
Total RNA extraction was performed with tissue lyser (Qiagen) in
TriRiagentTM (Sigma) and was reverse-transcribed using the
QuantiTect Reverse Transcription kit (Qiagen). Quantitative PCR
was performed on an ABI PRISM 7500 SDS (Applied Biosystems),
using premade 6-carboxyfluorescein (FAM)-labeled TaqMan as-
says for HPRT1, IL-6, IL6Rα, gp130, SOCS3, Utrn, TNFα, IL1β, IL-
1ra, SLPI, Pax-7, Desmin (Applied Biosystems). The relative level
for each gene was calculated using the 2-DDCt method and re-
ported as mean fold change in gene expression.
Flow cytometry
Isolated diaphragm muscles were dissociated from wild-type,
mdx and mdx/IL6 mice both mechanically, by mincing them
into a coarse slurry with scissors, and enzymatically, using
0.2% collagenase type II (Sigma) in PBS for 90 min at 37°C (65).
The isolated cells were then filtered through a 40 µm cell strainer
(Falcon) and incubated with the following antibodies (10 ng/ml):
CD31-PECy7, CD45-eFluor 450 (eBioscience); Sca-1-FITC (Macs),
CD34-APC (BD Pharmigen) and α7integrin-PE (R&D Systems
Inc.). A subsequent incubation with 7-Aminoactinomycin D
(Sigma) was performed. Flow cytometry analysis was performed
on a CyANADPDAKO and Summit 4.3 softwarewas used for data
acquisition and analysis.
Statistical analysis
Statistical analysis was performed with GraphPad Prism Soft-
ware. All data, if not differently specified, were expressed as
mean ± SEM. Difference among groups, if not differently speci-
fied, were assessed with one-way ANOVA with a Bonferroni
post test or Dunn’s post Test, and between pairs with Mann–
Whitney test or Student’s t-test assuming two-tailed distribu-
tions. Statistical comparisons of survival were made with the
long-rank test. Sample size was predetermined based on the
variability observed in preliminary and similar experiments. All
experiments requiring animalmodelswere subjected to random-
ization based on litter. P < 0.05 is considered statistically
significant.
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